Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Chemomab Therapeutics Ltd ADR (CMMB)

$2.72 +0.02 (0.74%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	14.07M
Revenue (ttm)	0.00
Net Income (ttm)	-13.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	165,900
Avg Vol	112,325
Day's Range	N/A - N/A
Shares Out	5.17M
Stochastic %K	82%
Beta	0.57
Analysts	Strong Sell
Price Target	$26.50

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building 7, Kiryat Atidim, Tel Aviv, Israel

DLTT4489 Oct. 4 at 11:41 AM

$CMMB Company and big pumpers send them here.

0 · Reply

JoeShmoDoe Oct. 4 at 1:25 AM

$CMMB where are all you fake ass pumpers coming from?

0 · Reply

JoeShmoDoe Oct. 4 at 1:23 AM

$CMMB if you want a low float stock to take your money. This it!!

0 · Reply

JoeShmoDoe Oct. 4 at 1:19 AM

$CMMB

0 · Reply

JoeShmoDoe Oct. 4 at 1:19 AM

$CMMB lol, who buys this shit. No one. Lmao

0 · Reply

Vikingsstrade Oct. 3 at 5:41 PM

$DRIO $USAS $CMMB $SUGP Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.

1 · Reply

Snptrader Oct. 3 at 1:24 PM

$CMMB

2 · Reply

Newmoves Oct. 3 at 11:30 AM

$CMMB what has Adi Moore done here?

1 · Reply

MoonCowBoy Oct. 2 at 11:49 PM

$GDHG $DRIO $USAS $CMMB N

1 · Reply

DLTT4489 Oct. 2 at 8:29 PM

$CMMB oh wow, news out 😅😅

0 · Reply

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:00 AM EDT - 7 weeks ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 30, 2025, 8:00 AM EDT - 3 months ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

Jun 11, 2025, 8:00 AM EDT - 4 months ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Jun 3, 2025, 8:00 AM EDT - 4 months ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

May 15, 2025, 8:00 AM EDT - 5 months ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 8:00 AM EDT - 5 months ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 21, 2025, 8:00 AM EDT - 5 months ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Apr 15, 2025, 8:00 AM EDT - 6 months ago

Chemomab Announces New Medical and Clinical Appointments

Mar 27, 2025, 3:18 PM EDT - 6 months ago

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Mar 27, 2025, 8:30 AM EDT - 6 months ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 6, 2025, 8:00 AM EST - 7 months ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 3, 2025, 8:00 AM EST - 7 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Feb 19, 2025, 7:00 AM EST - 8 months ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Dec 3, 2024, 7:00 AM EST - 10 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 19, 2024, 7:00 AM EST - 11 months ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 7:38 AM EDT - 1 year ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 1 year ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 1 year ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 1 year ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 4:15 PM EST - 2 years ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Oct 26, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

Jun 28, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

DLTT4489 Oct. 4 at 11:41 AM

$CMMB Company and big pumpers send them here.

0 · Reply

JoeShmoDoe Oct. 4 at 1:25 AM

$CMMB where are all you fake ass pumpers coming from?

0 · Reply

JoeShmoDoe Oct. 4 at 1:23 AM

$CMMB if you want a low float stock to take your money. This it!!

0 · Reply

JoeShmoDoe Oct. 4 at 1:19 AM

$CMMB

0 · Reply

JoeShmoDoe Oct. 4 at 1:19 AM

$CMMB lol, who buys this shit. No one. Lmao

0 · Reply

Vikingsstrade Oct. 3 at 5:41 PM

1 · Reply

Snptrader Oct. 3 at 1:24 PM

$CMMB

2 · Reply

Newmoves Oct. 3 at 11:30 AM

$CMMB what has Adi Moore done here?

1 · Reply

MoonCowBoy Oct. 2 at 11:49 PM

$GDHG $DRIO $USAS $CMMB N

1 · Reply

DLTT4489 Oct. 2 at 8:29 PM

$CMMB oh wow, news out 😅😅

0 · Reply

1Spartantrade1 Oct. 2 at 6:21 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CMMB $AKAN $SUGP $OP

1 · Reply

naeddel Oct. 2 at 7:28 AM

$CMMB ...results maybe soon?🤔🙂 https://clinicaltrials.gov/study/NCT04595825?term=chemomab&rank=5

1 · Reply

DLTT4489 Oct. 1 at 1:13 PM

$CMMB

0 · Reply

DLTT4489 Oct. 1 at 1:12 PM

$CMMB its close to be delisted

0 · Reply

MUBSN Oct. 1 at 9:10 AM

$CMMB early premarket activity

0 · Reply

DLTT4489 Sep. 30 at 8:25 PM

$CMMB Told you 😁😁

0 · Reply

DLTT4489 Sep. 30 at 7:21 PM

$CMMB 😁😁😁

0 · Reply

MUBSN Sep. 30 at 7:05 PM

$CMMB we are close

0 · Reply

DLTT4489 Sep. 30 at 2:02 PM

$CMMB the bid now is @ $40 after 1/40 RS 🤣🤣🤣🤣

0 · Reply

DLTT4489 Sep. 30 at 2:01 PM

$CMMB drop drop drop drop it

0 · Reply

dom3 Sep. 30 at 1:27 PM

$CMMB Actually the pre opening is 2.71 to 2.80.

0 · Reply

dom3 Sep. 30 at 1:26 PM

$CMMB Is this really up to 2.85 or another fadeout at opening. In any event, it continues to build a very bullish base.

1 · Reply

1.0.0